Astellas Pharma Inc. (YPH.BE) and Medivation, Inc. (MDVN) Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
5/24/2013 10:04:49 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
TOKYO & SAN FRANCISCO--(BUSINESS WIRE)--Astellas Pharma Inc. (TOKYO: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that Astellas has submitted an application for marketing approval of enzalutamide (generic name) to the Ministry of Health, Labour and Welfare in Japan for the treatment of prostate cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by